Simponi Seen to Show Promise as Short-Term Treatment for Ulcerative Colitis

Simponi Seen to Show Promise as Short-Term Treatment for Ulcerative Colitis
An observational study of the TNF blocker Simponi (golimumab) in patients with ulcerative colitis found that it is a promising short-term treatment, but a large proportion of patients needed more of it after a few months to keep its benefits. Patients who had not previously taken drugs blocking TNF-alpha were also seen to be more likely to respond to the treatment. Researchers at the University of Valencia in Spain — who published "Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study" in the World Journal of Gastroenterology — recruited 33 ulcerative colitis patients from several clinics in the region. A majority, 70%, had extensive disease at the study's start. All the patients had an endoscopic Mayo score of 2 or 3, indicating moderate to severe disease. Simponi is an antibody that blocks the actions of the cytokine TNF-alpha. Using such a medicine is common for treating ulcerative colitis, so the research team paid particular attention to the responses of patients who had been treated with the TNF blockers Remicade (infliximab) or Humira (adalimumab). Only 27.3 percent had never received such treatment. Among those who had been treated with TNF blockers, 25 percent stopped the treatment because their condition did not respond to it, and a 58.3 percent had a failed or lost response, meaning they did not respond to the treatment or did but the effect did not last. Researchers measured response using the Physician Gl
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *